Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Histopathology
|
September 7, 2016
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target
Christina I Selinger, Bob T Li, Nick Pavlakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy
Natasha B Leighl, Heather L Shepherd, Phyllis N Butow, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Karim Fizazi, Pablo González Mella, Daniel Castellano, et al.
The Lancet. Oncology
|
October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith, Josep Piulats, Tilman Todenhöfer, et al.
JACC. Advances
|
June 28, 2024
Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus
Claudia Toro, Ben Felmingham, Sophie Jessop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal for Immunotherapy of Cancer
|
June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
European Urology Oncology
|
February 22, 2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide
Barak Talmor, Carole A Harris, Christopher Gianacas, et al.
The Lancet. Oncology
|
September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun A Azad, Mathias Bressel, Hsiang Tan, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Histopathology
|
September 7, 2016
Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target
Christina I Selinger, Bob T Li, Nick Pavlakis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 21, 2025
Safety and Efficacy of Tarlatamab in patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Rahul Aggarwal, Sylvie Rottey, Alice Bernard-Tessier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2011
Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy
Natasha B Leighl, Heather L Shepherd, Phyllis N Butow, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 22, 2021
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Karim Fizazi, Pablo González Mella, Daniel Castellano, et al.
The Lancet. Oncology
|
October 30, 2025
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith, Josep Piulats, Tilman Todenhöfer, et al.
JACC. Advances
|
June 28, 2024
Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus
Claudia Toro, Ben Felmingham, Sophie Jessop, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal for Immunotherapy of Cancer
|
June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
European Urology Oncology
|
February 22, 2026
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide
Barak Talmor, Carole A Harris, Christopher Gianacas, et al.
The Lancet. Oncology
|
September 18, 2024
Sequential [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Arun A Azad, Mathias Bressel, Hsiang Tan, et al.
Page
of 5